Amongst the different PIM inhibitors developed, PIM447 represents a particularly attractive one due to its activity as a Pan-PIM inhibitor and also due to the fact that it is the first of its class to have reached clinical development as a single agent in MM with promising preliminary efficacy results [9]. The gene discussed is PIM1; the disease is Miyoshi myopathy.